Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Back view image of young businessman standing against business sketch
2021 was a busy deal-making year in big pharma, with M&A up slightly and alliances down a bit • Source: Shutterstock

Roche Holding AG, Genentech, Inc.  and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all categories, including mergers and acquisitions, licensing and partnerships, and divestments and out-licensing. That pace decreased substantially, however, from a total of 34 deals under the Roche umbrella in 2020, when the emerging COVID-19 pandemic spurred partnering activity but tamped down the M&A market a bit.

By total potential value – comprising upfront payment as well as earnouts such as milestone payments, research funding and option/licensing...

More from Growth

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.